JPM 2022: Sanofi has designs on creating Big Pharma's 'strongest' immunology franchise, CFO says

Sanofi has been no stranger to the biopharma dealmaking circuit under CEO Paul Hudson, and last year it inked a handful of biotech buyouts for mRNA, an FDA-approved transplant med and more. But Sanofi's busy 2021 doesn't mean the company will shy away from potential future deals, its CFO said.